Search Report

Talk to an AnalystTalk to an Analyst

Loading page data

Please wait a moment

sales@persistencemarketresearch.com

Second Floor, 150 Fleet Street,
London, EC4A 2DQ.

+44 203-837-5656

108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018

+1 646-878-6329

IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.

+91 906 779 3500

Quick Links

Careers Terms & Conditions Return Policy Market Research Report

Customer FAQ’s Privacy Policy Sitemap

Our Partners

Secure Payments Through

Connect With Us -

Psychedelic API Market Size, Share & Growth Trends, 2032

Pharmaceuticals
Psychedelic API Market

Psychedelic API Market Size, Share, and Growth Forecast for 2025 - 2032

Psychedelic API Market by Product Type (API-Grade Psilocybin, API-Grade DMT, LSD API, MDMA API, Ketamine API), API Compound (Active Plant Components, Novel Synthetic Compounds, Metabolites, Isotopically Labelled Standards), Source, Grade, Application, and Regional Analysis

ID: PMRREP33267

February 2025

167 Pages

Author : Abhijeet Surwase

Healthcare

Psychedelic API Market Size and Trends

The global psychedelic API market size is anticipated to rise from US$ 2.4 Bn in 2025 to US$ 5.6 Bn by 2032. It is projected to witness a CAGR of 13.2% from 2025 to 2032.

The focus on psychedelic-assisted therapy is driving demand for pharmaceutical-grade psychedelic active pharmaceutical ingredients like psilocybin, MDMA, LSD, and DMT. Clinical research has demonstrated the efficacy of psychedelics in treating mental health disorders, particularly treatment-resistant depression (TRD), PTSD, and anxiety.

In June 2023, the Multidisciplinary Association for Psychedelic Studies (MAPS) completed a Phase 3 clinical trial on MDMA-assisted therapy for PTSD, with significant success rates. Regulatory approvals are also expanding the market, with Australia legalizing MDMA and psilocybin for psychiatric use in July 2023.

Pharmaceutical companies like Compass Pathways and MindMed are investing in synthetic psychedelic API production and novel drug delivery systems to enhance therapeutic applications.

As per Persistence Market Research, the global psychedelic drug market is projected to reach US$ 8.3 Bn by 2028, with increasing partnerships between API manufacturers and pharmaceutical firms to streamline scalable production methods and cost-effective manufacturing of clinical-grade materials.

psychedelic api market outlook, 2019-2032

Key Highlights of the Psychedelic API Market

The clinical research in psychedelic therapies for mental health issues is boosting the demand for pharmaceutical-grade psychedelic APIs.
The increasing number of regulatory approvals for psychedelic-assisted therapies is enhancing the manufacturing prospects of GMP-certified API producers.
Rising investment in drug development utilizing compounds like psilocybin and MDMA is boosting the demand for high-purity research materials.
The growing range of mental health treatments suggests the potential for controlled therapeutic use of synthetic psychedelic APIs.
The development of innovative drug delivery systems for psychedelic compounds is driving advancements in API formulation and processing.
By type, API-Grade Psilocybin, are projected to experience the highest growth rate set to exhibit a CAGR of 13.6% through 2032, as per the Persistence Market Research.

Global Market Attributes	Key Insights
Psychedelic API Market Size (2025E)	US$ 2.4 Bn
Market Value Forecast (2032F)	US$ 5.6 Bn
Projected Growth (CAGR 2025 to 2032)	13.2%
Historical Market Growth (CAGR 2019 to 2024)	10.2%

Historical Growth and Course Ahead

UN Regulations on Research Transforms Psychedelic API Market

From 2019 to 2024, United Nations entities have intensified efforts to regulate prohibited substances in drug formulations, with organizations like the WHO advocating for alternative psychedelic drug forms to reduce misuse risks. In the observed period, the global psychedelic API industry witnessed a CAGR of 10.2%, with a strong emphasis on research and development for psychedelic drugs and medications.

The Johns Hopkins Center for Psychedelic and Consciousness Research, launched in September 2019, represents a major shift in the industry by focusing on medical applications of psilocybin. The US$ 17 Mn center, one of the largest of its kind, is researching psilocybin-assisted therapy for depression, opioid addiction, and PTSD, providing scientific validation for regulated psychedelic API use.

As regulatory pressure increases, businesses are developing synthetic alternatives to circumvent restrictions. Governments worldwide are also reconsidering psychedelic-assisted therapy, with Australia legalizing psilocybin and MDMA in July 2023. If successful, UN-backed regulations will reshape the psychedelic API market, pushing manufacturers toward compliant, medically approved formulations and fostering new drug development strategies in the mental health sector.

Psychedelic Substances Gains Traction for Mental Health Treatment with Promising Prospects

In the estimated timeframe from 2025 to 2032, the global market for psychedelic APIs is likely to showcase a CAGR of 13.2%. The World Health Organization highlights the rising incidence of mental health disorders such as PTSD, addiction, depression, and anxiety as a driving force behind the psychedelic substances market.

Traditional treatments like antidepressants and psychotherapy often have limitations, particularly for treatment-resistant conditions, leading researchers to explore psychedelics as alternative therapies.

Recent studies show psilocybin, the active compound in magic mushrooms, significantly reduces depression symptoms. A 2023 study found that 70% of participants experienced symptom relief after a single dose, reinforcing psilocybin’s potential.
Similarly, a 2022 trial by Compass Pathways reported 30% remission rates in patients with treatment-resistant depression.

With growing scientific validation, psychedelic-assisted therapy is gaining regulatory support. In July 2023, Australia became the first country to approve MDMA and psilocybin-assisted treatments for mental health disorders, setting a precedent for global adoption. This shift is reshaping psychiatric care, fueling demand for psychedelic APIs in the forthcoming period.

Get Your CustomizationGet Your Customization

Market Dynamics

Growth Drivers

Psychedelic Drug Development Expands Push Demand for High-Purity APIs

The rising investment in psychedelic-assisted therapies is accelerating the demand for high-purity research materials like psilocybin, MDMA, and LSD APIs. Leading pharmaceutical companies and research institutions are exploring their therapeutic potential in mental health disorders such as PTSD, depression, and substance abuse.

In January 2024, MAPS Public Benefit Corporation announced positive Phase 3 trial results for MDMA-assisted therapy for PTSD, strengthening its case for FDA approval.

Similarly, Compass Pathways is making progress with psilocybin therapy for treatment-resistant depression and has received FDA Breakthrough Therapy designation. In 2025, MDMA API is expected to capture 25% of the market, fueled by its late-stage clinical trials and anticipated regulatory approvals.

LSD API is projected to constitute 34% of the market, driven by increasing research into microdosing for depression and anxiety. Ketamine API, which is already in medical use, is predicted to hold 15% of the market, bolstered by the success of Spravato, an FDA-approved ketamine-based treatment for depression.

The demand for clinical research on mental disorders is envisioned to boost the demand for innovative psychedelic drugs in the upcoming period.

Market Restraining Factors

High Production Cost and Current Limitations in Patient Scalability

The production of psychedelic drugs encounters challenges in extracting active compounds from multi-compound organic sources, such as magic mushrooms. This process demands precise cultivation techniques to ensure chemical consistency.

The FDA has highlighted the high risk of abuse and the potential for addiction, which necessitates strict regulatory oversight. Furthermore, psychedelic-assisted therapy requires supervised psychotherapy, limiting the scalability of the market.

In February 2024, the Usona Institute reported difficulties in standardizing psilocybin extraction, leading to research into synthetic alternatives. At the same time, companies like MindMed and ATAI Life Sciences are developing bio-synthetic psychedelics to improve scalability and consistency.

The production cost of naturally sourced substances for psychedelic APIs is estimated to reach approximately US$ 675 Mn in 2024. According to studies, naturally sourced APIs are projected to account for 55% of the market by 2025. In contrast, the production and maintenance costs of synthetically sourced and bio-synthetically sourced APIs are comparatively higher.

Despite this, these substances tend to have lower market penetration than naturally sourced APIs. The higher production and maintenance costs of these substances may present challenges for market players with limited financial resources.

Request Free sampleRequest Free sample

Key Market Opportunities

Pharma-API Collaborations Presents Prospects for Psychedelic Drug Development

In an effort to promote psychedelic-based treatments, pharmaceutical firms and API manufacturers are collaborating strategically, emphasizing cost-effective and scalable production techniques for high-purity substances for clinical trials and therapeutic applications. For instance,

In January 2024, Compass Pathways partnered with Lonza Group to optimize psilocybin production, enhancing batch consistency for FDA-approved trials.
Similarly, MindMed collaborated with Nextage Therapeutics in February 2024 to co-develop MDMA-based treatments for PTSD.

With the rising prevalence of mental health disorders, such collaborative efforts are essential in reducing production costs, improving drug accessibility, and expediting regulatory approvals across the globe.

Companies like ATAI Life Sciences and Cybin are investigating novel formulations, and technical improvements and increasing clinical research expenditure are projected to fuel the growth of the worldwide psychedelic API market.

Psychedelic API Market Insights and Trends

API Compound Insights

Rise of Novel Synthetic Compounds in the Global Market Shows Avenues

In 2025, novel synthetic compounds are projected to account for 42% of the global market, dominating the segment due to their increasing production and availability as legal highs. These designer drugs, including phenethylamines, synthetic cathinones, and tryptamines, are often marketed as alternatives to traditional stimulants and hallucinogens.

Meanwhile, active plant components are expected to hold a 30% market share, driven by demand for natural psychoactive substances in clinical research and therapeutic applications.

Pharma manufacturers are projected to expand their research and development efforts for the improvements of innovative treatments for several mental disorders. For instance,

In March 2024, Compass Pathways expanded its research into synthetic psychedelic analogs, enhancing treatment options for depression and PTSD.

Similarly, MindMed partnered with MAPS to explore MDMA derivatives, strengthening the market for psychedelic-assisted therapy. Such initiatives are destined to prosper the consumer base for novel synthetic compounds in the projected period.

Grade Insights

Safety and Quality Maintenance in Accordance to Regulations Boost Demand for GMP-Grade Psychedelic APIs

The pharmaceutical industry's reliance on stringent manufacturing standards for psychedelic drug research, which ensure safety, effectiveness, and quality in clinical trials and therapeutic uses, is highlighted by the prediction that GMP-grade psychedelic APIs will account for 96% of the worldwide market in 2025.

Meanwhile, the non-GMP segment, consisting of research-based and experimental compounds outside regulated pharmaceutical pipelines, is expected to account for 4% of the market.

To obtain approvals for the production of psychedelic drugs, drug manufacturers are predicted to improve the production facilities and processes across the world. For instance,

In April 2024, Compass Pathways announced a new GMP-certified facility for psilocybin production, which will support large-scale clinical trials for treatment-resistant depression.
Similarly, ATAI Life Sciences expanded its GMP-grade psychedelic research to enhance mental health treatment options.

Such industry developments signal strong investment in controlled psychedelic drug manufacturing, ensuring regulatory approval and market expansion for therapeutic psychedelics.

psychedelic api market insights and key trends

Regional Insights and Trends

North America Leads the Psychedelic API Industry with Strong Regulatory Oversight

In 2025, North America is projected to hold 48% of the global psychedelic API market, with the U.S. alone accounting for 78% of the region’s market share. The dominance of psychedelics is attributed to strict regulatory oversight, increased investments in research and development, and increasing acceptance for mental health treatments.

The pharmaceutical manufacturing hubs in the region, particularly in New York-New Jersey, California, and Massachusetts, employ over 130,000 industry professionals and house numerous biotech and pharmaceutical giants. These professionals have leveraged the extensive knowledge and research available within the industry. For example,

In June 2024, the American Psychological Association (APA) emphasized the therapeutic potential of psychedelics, supporting ongoing research into MDMA- and psilocybin-based treatments.
Meanwhile, Compass Pathways and MindMed have expanded their clinical trials on psilocybin for depression.

With a projected CAGR of 7.3% from 2025 to 2032, North America’s psychedelic pharmaceutical sector is expected to thrive as regulatory pathways become clearer, driving commercialization and clinical adoption of psychedelic-based medicines.

Europe Expands Psychedelic Drug Research with Landmark Investments

Europe is rapidly emerging as a key market for psychedelic drug research, driven by increasing clinical studies on LSD, MDMA, and ketamine for mental health disorders. For instance,

In March 2024, the European Union (EU) launched a US$ 7 Mn research initiative to explore psychedelic-assisted treatments for conditions like depression, PTSD, and anxiety disorders. This marks one of the largest government-funded psychedelic studies in the world.

Pharmaceutical firms like Compass Pathways and atai Life Sciences are leading clinical trials on psilocybin and MDMA for treatment-resistant depression in countries like the U.K. and Netherlands. With rising regulatory support and investment in psychedelic medicine, Europe is poised to become a major hub for psychedelic-based therapies, significantly expanding the region’s mental health treatment landscape.

Asia Pacific Magnifies Psychedelic Drug and Biopharmaceutical Innovation for Mental Health

In the Asia Pacific, the development of psychedelic medications is projected to yield promising results for several mental disorders. In 2025, China's role as a leading API producer continues to expand, with investments in biopharmaceutical manufacturing to meet growing regional demand.

The region’s pharmaceutical sector is strengthening, with major biologics companies developing commercial-scale facilities for advanced drug production, including cell and gene therapies.

According to the United Nations Office on Drugs and Crime (UNODC), China remains a key hub in the global pharmaceutical supply chain, with its regulatory framework evolving to support safer production practices. Followed by India and Japan with the development of innovative therapies.

Additionally, India's advancements in cell therapies are shaping the future of personalized medicine, potentially leading to groundbreaking treatments for cancer and rare diseases in the Asia Pacific.

As regulatory oversight strengthens, Asia Pacific's role in API production and next-generation therapies is set to grow in the upcoming years.

Psychedelic API Market Competitive Landscape

Companies in the global psychedelic Active Pharmaceutical Ingredient (API) industry are focusing on offering a diverse range of APIs and actively participating in the development of new psychedelic drugs.

Venture capital firms are showing considerable interest and making significant investments in start-ups that are creating psychedelic medicines for various conditions, including PTSD and smoking cessation.

Partnerships between pharmaceutical companies and API manufacturers accelerate the development of psychedelic-based medications. Investment in scalable production methods improves manufacturing efficiency and reduces costs for clinical-grade materials.

Key Industry Developments

In November 2024, the Association for Prescription Psychedelics (APP) integrated prescription psychedelic medicines into healthcare for eligible patients, promoting government-sponsored research, public-private partnerships, patient-centric treatment, and healthcare infrastructure investments.
In June 2024, the University of Colorado Denver established the CU Denver Center for Psychedelic Research, focusing on the potential benefits and societal and economic implications of psychedelic drugs.
In December 2023, Lykos Therapeutics (formerly MAPS Public Benefit Corporation) completed Phase 3 clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) and submitted a New Drug Application to the U.S. FDA.
In April 2023, PharmAla Biotech and Filament Health collaborated to release GMP-certified MDMA capsules for clinical trials and patients worldwide, aiming to address the global shortage of MDMA and meet increasing demand in Australia.
In September 2022, Cybin Inc. announced that the innovative pipeline of experimental psychedelic treatments it has been developing and advancing was finished ahead of schedule.
In July 2022, BetterLife partnered with the Carleton University research team to seek further Mitacs funding for BETR-001 preclinical depression investigations.

Companies Covered in Psychedelic API Market

Core One Labs Inc.
Cayman Chemical Company (Matreya)
COMPASS Pathways plc
Beckley Psytech
Atai Life Sciences
Tryp Therapeutics
Filament Health
Ceruvia Lifesciences, LLC
BetterLife Pharma
Psygen Pharmaceutical
Mindset Pharma

Frequently Asked Questions

The market is set to reach US$ 2.4 Bn in 2025.

New York-New Jersey is home to over 3,200 life science companies, with 13 of the top 20 biopharmaceutical companies having their headquarters or major facilities in the region.

Core One Labs Inc., Cayman Chemical Company (Matreya), COMPASS Pathways plc, and Beckley Psytech are a few leading players.

The industry is estimated to rise at a CAGR of 13.2% through 2032.

North America is projected to hold the largest share of the industry in 2025.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading Report...

Pharmaceuticals
Psychedelic API Market

Psychedelic API Market Size, Share, and Growth Forecast for 2025 - 2032

Psychedelic API Market by Product Type (API-Grade Psilocybin, API-Grade DMT, LSD API, MDMA API, Ketamine API), API Compound (Active Plant Components, Novel Synthetic Compounds, Metabolites, Isotopically Labelled Standards), Source, Grade, Application, and Regional Analysis

ID: PMRREP33267

February 2025

167 Pages

Author : Abhijeet Surwase

Healthcare

Psychedelic API Market Size and Trends

The global psychedelic API market size is anticipated to rise from US$ 2.4 Bn in 2025 to US$ 5.6 Bn by 2032. It is projected to witness a CAGR of 13.2% from 2025 to 2032.

In June 2023, the Multidisciplinary Association for Psychedelic Studies (MAPS) completed a Phase 3 clinical trial on MDMA-assisted therapy for PTSD, with significant success rates. Regulatory approvals are also expanding the market, with Australia legalizing MDMA and psilocybin for psychiatric use in July 2023.

Pharmaceutical companies like Compass Pathways and MindMed are investing in synthetic psychedelic API production and novel drug delivery systems to enhance therapeutic applications.

psychedelic api market outlook, 2019-2032

Key Highlights of the Psychedelic API Market

The clinical research in psychedelic therapies for mental health issues is boosting the demand for pharmaceutical-grade psychedelic APIs.
The increasing number of regulatory approvals for psychedelic-assisted therapies is enhancing the manufacturing prospects of GMP-certified API producers.
Rising investment in drug development utilizing compounds like psilocybin and MDMA is boosting the demand for high-purity research materials.
The growing range of mental health treatments suggests the potential for controlled therapeutic use of synthetic psychedelic APIs.
The development of innovative drug delivery systems for psychedelic compounds is driving advancements in API formulation and processing.
By type, API-Grade Psilocybin, are projected to experience the highest growth rate set to exhibit a CAGR of 13.6% through 2032, as per the Persistence Market Research.

Global Market Attributes	Key Insights
Psychedelic API Market Size (2025E)	US$ 2.4 Bn
Market Value Forecast (2032F)	US$ 5.6 Bn
Projected Growth (CAGR 2025 to 2032)	13.2%
Historical Market Growth (CAGR 2019 to 2024)	10.2%

Historical Growth and Course Ahead

UN Regulations on Research Transforms Psychedelic API Market

The Johns Hopkins Center for Psychedelic and Consciousness Research, launched in September 2019, represents a major shift in the industry by focusing on medical applications of psilocybin. The US$ 17 Mn center, one of the largest of its kind, is researching psilocybin-assisted therapy for depression, opioid addiction, and PTSD, providing scientific validation for regulated psychedelic API use.

Psychedelic Substances Gains Traction for Mental Health Treatment with Promising Prospects

Recent studies show psilocybin, the active compound in magic mushrooms, significantly reduces depression symptoms. A 2023 study found that 70% of participants experienced symptom relief after a single dose, reinforcing psilocybin’s potential.
Similarly, a 2022 trial by Compass Pathways reported 30% remission rates in patients with treatment-resistant depression.

Get Your CustomizationGet Your Customization

Market Dynamics

Growth Drivers

Psychedelic Drug Development Expands Push Demand for High-Purity APIs

In January 2024, MAPS Public Benefit Corporation announced positive Phase 3 trial results for MDMA-assisted therapy for PTSD, strengthening its case for FDA approval.

Similarly, Compass Pathways is making progress with psilocybin therapy for treatment-resistant depression and has received FDA Breakthrough Therapy designation. In 2025, MDMA API is expected to capture 25% of the market, fueled by its late-stage clinical trials and anticipated regulatory approvals.

The demand for clinical research on mental disorders is envisioned to boost the demand for innovative psychedelic drugs in the upcoming period.

Market Restraining Factors

High Production Cost and Current Limitations in Patient Scalability

In February 2024, the Usona Institute reported difficulties in standardizing psilocybin extraction, leading to research into synthetic alternatives. At the same time, companies like MindMed and ATAI Life Sciences are developing bio-synthetic psychedelics to improve scalability and consistency.

Request Free sampleRequest Free sample

Key Market Opportunities

Pharma-API Collaborations Presents Prospects for Psychedelic Drug Development

In January 2024, Compass Pathways partnered with Lonza Group to optimize psilocybin production, enhancing batch consistency for FDA-approved trials.
Similarly, MindMed collaborated with Nextage Therapeutics in February 2024 to co-develop MDMA-based treatments for PTSD.

Psychedelic API Market Insights and Trends

API Compound Insights

Rise of Novel Synthetic Compounds in the Global Market Shows Avenues

Meanwhile, active plant components are expected to hold a 30% market share, driven by demand for natural psychoactive substances in clinical research and therapeutic applications.

Pharma manufacturers are projected to expand their research and development efforts for the improvements of innovative treatments for several mental disorders. For instance,

In March 2024, Compass Pathways expanded its research into synthetic psychedelic analogs, enhancing treatment options for depression and PTSD.

Grade Insights

Safety and Quality Maintenance in Accordance to Regulations Boost Demand for GMP-Grade Psychedelic APIs

Meanwhile, the non-GMP segment, consisting of research-based and experimental compounds outside regulated pharmaceutical pipelines, is expected to account for 4% of the market.

To obtain approvals for the production of psychedelic drugs, drug manufacturers are predicted to improve the production facilities and processes across the world. For instance,

In April 2024, Compass Pathways announced a new GMP-certified facility for psilocybin production, which will support large-scale clinical trials for treatment-resistant depression.
Similarly, ATAI Life Sciences expanded its GMP-grade psychedelic research to enhance mental health treatment options.

Such industry developments signal strong investment in controlled psychedelic drug manufacturing, ensuring regulatory approval and market expansion for therapeutic psychedelics.

psychedelic api market insights and key trends

Regional Insights and Trends

North America Leads the Psychedelic API Industry with Strong Regulatory Oversight

In June 2024, the American Psychological Association (APA) emphasized the therapeutic potential of psychedelics, supporting ongoing research into MDMA- and psilocybin-based treatments.
Meanwhile, Compass Pathways and MindMed have expanded their clinical trials on psilocybin for depression.

Europe Expands Psychedelic Drug Research with Landmark Investments

Europe is rapidly emerging as a key market for psychedelic drug research, driven by increasing clinical studies on LSD, MDMA, and ketamine for mental health disorders. For instance,

In March 2024, the European Union (EU) launched a US$ 7 Mn research initiative to explore psychedelic-assisted treatments for conditions like depression, PTSD, and anxiety disorders. This marks one of the largest government-funded psychedelic studies in the world.

Asia Pacific Magnifies Psychedelic Drug and Biopharmaceutical Innovation for Mental Health

The region’s pharmaceutical sector is strengthening, with major biologics companies developing commercial-scale facilities for advanced drug production, including cell and gene therapies.

According to the United Nations Office on Drugs and Crime (UNODC), China remains a key hub in the global pharmaceutical supply chain, with its regulatory framework evolving to support safer production practices. Followed by India and Japan with the development of innovative therapies.

As regulatory oversight strengthens, Asia Pacific's role in API production and next-generation therapies is set to grow in the upcoming years.

Psychedelic API Market Competitive Landscape

Key Industry Developments

In November 2024, the Association for Prescription Psychedelics (APP) integrated prescription psychedelic medicines into healthcare for eligible patients, promoting government-sponsored research, public-private partnerships, patient-centric treatment, and healthcare infrastructure investments.
In June 2024, the University of Colorado Denver established the CU Denver Center for Psychedelic Research, focusing on the potential benefits and societal and economic implications of psychedelic drugs.
In December 2023, Lykos Therapeutics (formerly MAPS Public Benefit Corporation) completed Phase 3 clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) and submitted a New Drug Application to the U.S. FDA.
In April 2023, PharmAla Biotech and Filament Health collaborated to release GMP-certified MDMA capsules for clinical trials and patients worldwide, aiming to address the global shortage of MDMA and meet increasing demand in Australia.
In September 2022, Cybin Inc. announced that the innovative pipeline of experimental psychedelic treatments it has been developing and advancing was finished ahead of schedule.
In July 2022, BetterLife partnered with the Carleton University research team to seek further Mitacs funding for BETR-001 preclinical depression investigations.

Companies Covered in Psychedelic API Market

Core One Labs Inc.
Cayman Chemical Company (Matreya)
COMPASS Pathways plc
Beckley Psytech
Atai Life Sciences
Tryp Therapeutics
Filament Health
Ceruvia Lifesciences, LLC
BetterLife Pharma
Psygen Pharmaceutical
Mindset Pharma

Frequently Asked Questions

The market is set to reach US$ 2.4 Bn in 2025.

New York-New Jersey is home to over 3,200 life science companies, with 13 of the top 20 biopharmaceutical companies having their headquarters or major facilities in the region.

Core One Labs Inc., Cayman Chemical Company (Matreya), COMPASS Pathways plc, and Beckley Psytech are a few leading players.

The industry is estimated to rise at a CAGR of 13.2% through 2032.

North America is projected to hold the largest share of the industry in 2025.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Report Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn/Mn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Type API Compound Source Grade Application Region
Competitive Analysis	Core One Labs Inc. Cayman Chemical Company (Matreya) COMPASS Pathways plc Beckley Psytech Atai Life Sciences Tryp Therapeutics Filament Health Ceruvia Lifesciences, LLC BetterLife Pharma Psygen Pharmaceutical Mindset Pharma
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Report Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn/Mn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Type API Compound Source Grade Application Region
Competitive Analysis	Core One Labs Inc. Cayman Chemical Company (Matreya) COMPASS Pathways plc Beckley Psytech Atai Life Sciences Tryp Therapeutics Filament Health Ceruvia Lifesciences, LLC BetterLife Pharma Psygen Pharmaceutical Mindset Pharma
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Quick Links

Our Partners

Secure Payments Through

Psychedelic API Market Size, Share, and Growth Forecast for 2025 - 2032

Psychedelic API Market by Product Type (API-Grade Psilocybin, API-Grade DMT, LSD API, MDMA API, Ketamine API), API Compound (Active Plant Components, Novel Synthetic Compounds, Metabolites, Isotopically Labelled Standards), Source, Grade, Application, and Regional Analysis

Psychedelic API Market Size and Trends

Historical Growth and Course Ahead

Market Dynamics

Market Restraining Factors

Key Market Opportunities

Psychedelic API Market Insights and Trends

Regional Insights and Trends

Psychedelic API Market Competitive Landscape

Companies Covered in Psychedelic API Market

Frequently Asked Questions

How Big is the Psychedelic API Market?

Which is the biggest pharmaceutical hub?

What companies are investing in psychedelics?

What is the Projected Growth Rate of the Psychedelic API Industry?

Which Region Holds the Largest Share in the Psychedelic API Industry?

Related Reports

Saudi Arabia Pharmaceuticals Market Size, Share, Growth, and Forecast, 2026 to 2033

Hairy Cell Leukemia Treatment Market Size, Share, and Growth Forecast 2026 - 2033

Food Allergen Testing Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

Ferritin Testing Market Size, Share, and Growth Forecast 2026 - 2033

Fentanyl Market Size, Share, and Growth Forecast, 2026 - 2033

Wart Remover Market Size, Share, and Growth Forecast, 2026 – 2033

Related Reports

Saudi Arabia Pharmaceuticals Market Size, Share, Growth, and Forecast, 2026 to 2033

Hairy Cell Leukemia Treatment Market Size, Share, and Growth Forecast 2026 - 2033

Food Allergen Testing Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

Ferritin Testing Market Size, Share, and Growth Forecast 2026 - 2033

Fentanyl Market Size, Share, and Growth Forecast, 2026 - 2033

Wart Remover Market Size, Share, and Growth Forecast, 2026 – 2033

Research Methodology Framework for Market Research Excellence

Core Research Philosophy

Capturing Key Information and Events

TAM-SAM-SOM Framework Implementation

Validation & Cross-Verification

Forecasting & Projection Modeling

Comprehensive Data Collection Strategy

Primary Research Excellence

Quality Assurance & Validation Framework

Methodology Validation & Credibility

Interested in this report?

Clients

Media Citation

Get In Touch

Psychedelic API Market Size, Share, and Growth Forecast for 2025 - 2032

Psychedelic API Market by Product Type (API-Grade Psilocybin, API-Grade DMT, LSD API, MDMA API, Ketamine API), API Compound (Active Plant Components, Novel Synthetic Compounds, Metabolites, Isotopically Labelled Standards), Source, Grade, Application, and Regional Analysis

Psychedelic API Market Size and Trends

Historical Growth and Course Ahead

Market Dynamics

Market Restraining Factors

Key Market Opportunities

Psychedelic API Market Insights and Trends

Regional Insights and Trends

Psychedelic API Market Competitive Landscape

Companies Covered in Psychedelic API Market

Frequently Asked Questions

How Big is the Psychedelic API Market?

Which is the biggest pharmaceutical hub?

What companies are investing in psychedelics?

What is the Projected Growth Rate of the Psychedelic API Industry?

Which Region Holds the Largest Share in the Psychedelic API Industry?

Related Reports

Saudi Arabia Pharmaceuticals Market Size, Share, Growth, and Forecast, 2026 to 2033

Hairy Cell Leukemia Treatment Market Size, Share, and Growth Forecast 2026 - 2033

Food Allergen Testing Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

Ferritin Testing Market Size, Share, and Growth Forecast 2026 - 2033

Fentanyl Market Size, Share, and Growth Forecast, 2026 - 2033

Wart Remover Market Size, Share, and Growth Forecast, 2026 – 2033

Related Reports

Saudi Arabia Pharmaceuticals Market Size, Share, Growth, and Forecast, 2026 to 2033

Hairy Cell Leukemia Treatment Market Size, Share, and Growth Forecast 2026 - 2033

Food Allergen Testing Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

Ferritin Testing Market Size, Share, and Growth Forecast 2026 - 2033

Fentanyl Market Size, Share, and Growth Forecast, 2026 - 2033

Wart Remover Market Size, Share, and Growth Forecast, 2026 – 2033

Research Methodology Framework for Market Research Excellence